Jasper Therapeutics operates as a clinical-stage biotechnology firm developing treatments for immune-mediated diseases, with candidates including a dual-complement inhibitor and a dual-acting anti-CD79BxCD32B antibody. Amgen licensed worldwide rights to JSP191 to the company alongside Stanford University translational science and materials. Jasper focuses on safer conditioning and therapeutic agents that broaden the use of curative hematopoietic stem cell transplants and gene therapies.

Jasper evaluates KP104, a potential dual-complement inhibitor, in paroxysmal nocturnal hemoglobinuria and IgA nephropathy; the pipeline includes Vensobafusp alfa (KP104), briquilimab and KP701 with targets spanning the immune system. Briquilimab, an anti-KIT antibody, is studied as a conditioning agent for stem cell transplant and for mast cell diseases including chronic urticarias and allergic asthma. KP701 is a dual-acting anti-CD79BxCD32B monoclonal antibody for autoantibody-mediated disorders advancing to the clinic.